Schizophrenia spectrum and other psychotic disorders afflict the bulk of chronically mentally ill individuals . Thus, antipsychotic medications form the core of pharmacological treatment in complex treatment-resistant populations .
Unfortunately, adherence to oral antipsychotics in outpatient settings, even when defined as taking only 80% of prescribed doses, is consistently less than 50% [3, 4]. Due to enhanced adherence, long-acting injectable (LAI) antipsychotics have proven superior to their oral counterparts in reducing crime and violence, as well as in increasing longevity [5–8].
Despite their demonstrated superiority to oral antipsychotics in several areas relevant to chronically mentally ill populations (e.g. improving treatment adherence with a consequential decrease in violence), LAI antipsychotics remain underutilized [9, 10].